We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol). (PATROL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00891124
First Posted: May 1, 2009
Last Update Posted: November 3, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care nationwide.

Condition
Glycemia Hypertension Hyperlipidemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multi-center, Prospective, Observational Study to Assess the Effect of Patient Education Related to CV Risk Factors in Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline [ Time Frame: At baseline and Endpiont (after 2months) ]

Secondary Outcome Measures:
  • The treatment goal of risk factors is based on ADA guideline. [ Time Frame: At baseline and Endpiont (after 2months) ]

Enrollment: 4045
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
1
Type II DM and Hypertension and/or Hyperlipidemia

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Type II DM and Hypertension and/or Hyperlipidemia
Criteria

Inclusion Criteria:

  • Patients who had been diagnosed with type II diabetes mellitus
  • Patients with hypertension and / or hyperlipidemia
  • Patients who had agreed to Informed

Exclusion Criteria:

  • Patients who had been diagnosed with type I diabetes mellitus
  • Patients with neither hypertension and hyperlipidemia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00891124


Locations
Korea, Republic of
Research Site
Busan, Korea, Republic of
Research Site
Cheiju, Korea, Republic of
Research SIte
Daegu, Korea, Republic of
Research Site
Gwangju, Korea, Republic of
Research Site
Hongsung, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Research Site
Sungman, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Joonwoo Bahn ASTRAZENECA, Korea Medical Department
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00891124     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/2
First Submitted: April 28, 2009
First Posted: May 1, 2009
Last Update Posted: November 3, 2009
Last Verified: November 2009

Keywords provided by AstraZeneca:
Hypertension
Type II DM
Hyperlipidemia
Glycemia
ADA 2008 guideline
Patient Consultation

Additional relevant MeSH terms:
Hypertension
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hyperlipidemias
Hyperlipoproteinemias
Vascular Diseases
Cardiovascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Dyslipidemias
Lipid Metabolism Disorders